SIDOVIS

This brand name is authorized in Estonia, Turkey

Active ingredients

The drug SIDOVIS contains one active pharmaceutical ingredient (API):

1 Cidofovir
UNII JIL713Q00N - CIDOFOVIR

Cidofovir suppresses HCMV replication by selective inhibition of viral DNA synthesis. Biochemical data support selective inhibition of HSV-1, HSV-2 and HCMV DNA polymerases by cidofovir diphosphate, the active intracellular metabolite of cidofovir.

Read about Cidofovir

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
J05AB12 Cidofovir J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors
Discover more medicines within J05AB12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1771433
Country: TR ฤฐlaรง ve Tฤฑbbi Cihaz Kurumu Identifier(s): 8680952000772

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈